BUZZ-NeuroSense rises after U.S. FDA clears late-stage ALS drug trial** Shares of drug developer NeuroSense Therapeutics' NRSN.O rise 9% to $1.20 during early trading
** Co says has received clearance from the U.S. FDA to begin late-stage clinical trial of its experimental drug, PrimeC, for amyotrophic lateral sclerosis or ALS
** Amyotrophic lateral sclerosis is a fatal neurodegenerative disease
** The late-stage trial will enroll 300 patients in U.S. and EU; aims to confirm prior mid-stage results - NRSN
** Co's PrimeC combines two approved drugs to slow ALS progression by targeting inflammation and RNA regulation, co says
** Including session's move, stock down ~1.7% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments